Pnd98 - Determining the Value of Ocrevus® (Ocrelizumab) for the Treatment of Multiple Sclerosis in Spain by Multi-Criteria Decision Analysis (Mcda)
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2064
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV